Accessing surgical care is of profound significance that face remote African communities due to insufficient healthcare means and infrastructure. Deploying mobile surgical units (MSUs) have present a potential solution to underserved populations in rural Africa to address said issues. The aim of this narrative review is to examine the role of MSU utilization in remote African communities to meet surgical needs and evaluate how this has affected healthcare provision. To identify studies focusing on the dissemination of MSUs in remote African communities covered countries such as Uganda, Kenya, Tanzania, Nigeria, and Ethiopia, and we employed a plethora of electronic search databases including PubMed/Medline, Google Scholar, Scopus and other relevant literature sources. Inclusion criteria were studies on MSUs in remote African communities, while exclusion criteria involved non- African or urban-focused studies. This review highlights that the current literature depicts that application of MSUs bring a positive impact in providing timely and quality surgical care to remote African communities. Frequent interventions, such as minor surgeries, obstetric procedures, and major trauma control, have been performed on MSUs. In settings with shortages of human resources and clinical equipments, these units have improved patient outcomes, reduced healthcare disparities, and increased access to emergency surgical care. While challenges such as financial constraints and surgical sustainability have been noted, the need for interdisciplinary collaboration and the advantages of MSU deployment often help mitigate these obstacles. A lack of surgical care for individuals living in remote African domiciles may be addressed via MSU application. Through delivering fundamental surgical services directly to underserved populations, MSUs may potentially prevent disabilities, save countless lives, and enhance overall health outcomes in African remote communities. To guarantee the long-term feasibility and sustainability of MSU programs in Africa, however, more funding must be allocated to infrastructure, supplies, and relevant education.

Introduction: Since the advent of highly active antiretroviral therapy (HAART), morbidity and mortality rates associated with human immunodeficiency virus (HIV) have significantly decreased leading to prolonged life span of Individuals living with HIV due to the effectiveness of antiretroviral therapy. However, this prolonged lifespan alone does not fully account for the increased incidence of cardiometabolic complications. These complications result from a complex interplay of factors such as chronic inflammation, immune activation, ART‐related metabolic effects, and lifestyle changes. which contribute to elevated morbidity and mortality rates, therefore requiring a deeper understanding and setting effective management strategies. This review aims at providing insights and a nuanced understanding of the relationship between HIV and cardiometabolic disorders, explore their clinical implications and adapt optimal management strategies to address the multifaceted challenges at the intersection of HIV and cardiometabolic health, ultimately enhancing patient outcomes and quality of life.Methods: Data retrieval was conducted using a predetermined search strategy from medical journals that were published in bibliographical databases like PubMed, Science Direct and Embase. This review systematically considered and synthesized current literature on the association between cardiometabolic challenges and HIV.Results: This review provides a detailed exploration of the interrelationship between HIV and cardiometabolic challenges, with an emphasis on insights, impact, and best practices for optimal management. It underscores the high risk of cardiovascular disease, insulin resistance, dyslipidemia, and lipodystrophy in people living with HIV. Recommendations include evidence‐based approaches such as routine cardiometabolic risk. Prevention, screening, management, lifestyle interventions (diet and exercise), and optimizing ART regimens to reduce the negative health outcomes experienced by people living with HIV and to direct clinical practice. To reduce health issues, enhance clinical results, and improve the long‐term quality of life for people living with HIV, it is important to early identify cardiovascular risk factors and to follow customized prevention and management methods.Conclusion: This review shows that early detection through regular screening is pivotal through collaboration between healthcare providers, researchers, and policymakers which will allow for timely interventions and drive innovation and address evolving challenges to enhancing the quality of life for individuals living with HIV. Continuing to do research and advocacy efforts, will not only advance knowledge but also optimize the long‐term health outcomes for people living with HIV.

Background: The side effects of two related chemicals, ammonium thioglycolate (ATG) and thioglycolic acid (TGA) have been widely highlighted in the world of cosmetics. These thioglycolate compounds are considered essential ingredients in a new technique known as brow lamination. This technique is widely used nowadays, with the aim of changing the eyebrow shape. Aims: To our knowledge, this is the first study to address the possible side effects of brow lamination. Results: The hydrophilic characteristic of ATG and TGA reflects their transdermal absorption through the intracellular and transappendageal pathways. These compounds can affect the skin through allergic contact dermatitis (ACD), characterized by skin irritation, dryness, and erythema. Moreover, these thioglycolates can alter several mechanical and chemical reactions in the eyebrows' hair, therefore affecting their shape, structure, and pigmentation. In addition, these chemicals contained in brow lamination can exert systemic manifestations, at the level of the reproductive, ocular, respiratory, and endocrine systems. Conclusion: More studies should be elaborated to shed light on the possible side effects of this trend. Additionally, further regulations should be taken into consideration to ensure the concentration and the measures applied are convenient to minimize these side effects.

Background: Adult acne vulgaris is a chronic inflammatory skin condition that primarily affects females. Initial management includes topical and oral medications, but important limitations include ineffectiveness, nonadherence, and adverse effects. Spironolactone has shown good results in off‐label acne management.Aims: We aim to conduct a systematic review and meta‐analysis exploring the safety and efficacy of oral spironolactone for females with acne.Methods: We searched PubMed, Embase, and Cochrane for randomized controlled trials (RCTs) comparing oral spironolactone in women with acne to placebo. The primary endpoint was the objective assessment of acne improvement. Secondary endpoints included subjective assessment and adverse events. Statistical analysis was performed using Review Manager 5.4. Heterogeneity was assessed with I² statistics.Results: We included 563 patients from 5 RCTs, of which 251 (42.9%) received spironolactone. Objective assessment of acne improvement (OR 6.59; 95% 3.50–12.43; p < 0.00001; I² = 0%) was sixfold higher in the spironolactone group compared with placebo. Subjective assessment showed no difference between the two groups (OR 5.22; 95% 0.62–44.24; p < 0.13; I² = 85%). Menstrual irregularities (OR 1.09; 95% 0.37–3.25; p = 0.88; I² = 33%) and breast enlargement (OR 1.37; 95% 0.79–2.38; p = 0.26; I² = 0%) were nonsignificant in patients taking spironolactone. Trial sequential analysis (TSA) confirmed that the required sample size was reached, favoring spironolactone over placebo.Conclusion: Our study suggests that oral spironolactone improves acne in female patients compared to placebo without increasing risks; thus, it should be elevated from “off‐label” use to an officially recommended standard of care.PROSPERO Registration: CRD42024626984.